Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (Type 2) diabetes mellitus

Diabetic Medicine

Volumn 13, Issue 8, 1996, Pages 753-757

  Nagi, D K ^a,b   Ali, V Mohamed ^a   Yudkin, J S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

Author keywords

des 31,32 proinsulin; Insulin; Metformin; Proinsulin

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; PLACEBO; PROINSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME IMMUNOASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ETHNIC GROUPS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROINSULIN; PROTEIN PRECURSORS;

EID: 8944248809     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199608)13:8<753::AID-DIA163>3.0.CO;2-Z     Document Type: Article

References (31)

1. Bailey CJ, Nattrass M. Treatment - Metformin. Bailliere's Clinical Endocrinology and Metabolism 1988; 2: 455-476.
2. Nagi DK, Yudkin JS. The effects of metformin on insulin resistance, risk factors for cardiovascular disease and plasminogen activator inhibitor in NIDDM subjects - a study of two ethnic groups. Diabetes Care 1993; 16: 621-629.
3. Prager R, Schernthaner C, Graf H. Effects of metformin on peripheral insulin sensitivity in non-insulin dependent diabetes mellitus. Diabete et Metabolisme 1986; 12: 346-350.
4. Nosadini R, Avogaro A, Trevisan R, Valerio A, Tessari P, Duner E, et al. Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes. Diabetes Care 1987; 10: 62-67.
5. DeFronzo RA, Barzilay N, Simonson DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301.
6. Clarke BF, Campbell IW. Comparison of metformin and chlorpropamide in non-obese maturity onset diabetics uncontrolled by diet. Br Med J 1977; 2: 1576-1578.
7. Clarke BF, Duncan LJP. Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics. Lancet 1968; i: 123-126.
8. Hermann LS, Melander A. Biguanides: basic aspects and clinical uses. In: Alberti KGMM, Defronzo RA, Keen HA, Zimmer PA, Eds. International Textbook of Diabetes Mellitus. Chichester: Wiley 1992: 773-795.
9. Yoshioka N, Kazuya T, Matsuda A, Iwamoto Y. Effects of dietary treatment on serum insulin and proinsulin response in newly diagnosed NIDDM. Diabetes 1989; 38: 262-267.
10. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987; 30: 698-702.
11. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PMS, et al. The relationship between concentrations of insulin, intact proinsulin, and 32-33 split proinsulin and cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1990; 33: 532-537.
12. Leahy JL. Increased proinsulin/insulin ratio in pancreas extracts of hyperglycemic rats. Diabetes 1993; 42: 22-27.
13. Leahy JL, Halban PA, Weir GC. Relative hypersecretion of proinsulin in rat model of NIDDM. Diabetes 1991; 40: 985-989.
14. Davies MJ, Metcalf J, Gray IP, Day JL, Hales CN. Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type 2 diabetes mellitus. Diabetic Med 1993; 10: 305-312.
15. Mohamed-Ali V, Gould M, Goubet S, Yudkin JS. The relationship between insulin, intact proinsulin, des 31,32 proinsulin and other cardiovascular risk factors in non-diabetic subjects. Diabetic Med 1993; 10 (suppl 2): P54.
16. Haffner SM, Mykkanen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR. The relationship of proinsulin and insulin to cardiovascular risk factors in non-diabetic subjects. Diabetes 1993; 42: 1297-1302.
17. Sobey WJ, Beer SF, Carrington CA, Clark PMS, Frank BH, Gray P, et al. Sensitive and specific two-site immunoradiometric assays to human insulin, proinsulin, 65-66 split and 32-33 split proinsulin. Biochem J 1989: 260; 535-541.
18. Mohamed-Ali V, Yudkin JS. An end-point amplified enzymoimmunoassay (IEMA) specific for human insulin. Clin Sci 1992; 82 (suppl 27) P4.
19. Mohamed-Ali V, Yudkin JS. Simple and highly sensitive microplate assays (IRMAs) for intact proinsulin and des 31,32 proinsulin. Diabetic Med 1993; 10 (suppl 1) P67.
20. Chmieiewska J, Ranby M, Wiman B. Evidence of a rapid inhibitor to tissue plasminogen activators in plasma. Thromb Res 1983; 31: 427-436.
21. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, et al. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989; i: 293-295.
22. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW, et al. Disproportionately elevated proinsulin in Pima Indians with non-insulin dependent diabetes mellitus. J Clin Endocrinol Metab 1990; 70: 1247-1253.
23. Davies MJ, Metcalf J, Day JL, Grenfell A, Hales CN, Gray IP. Improved Beta cell function, with reduction in secretion of intact and 32,33 split proninsulin, after dietary intervention in subjects with Type 2 diabetes mellitus. Diabetic Med 1994; 11: 71-78.
24. Elkeles RS, Heding LG, Paisey RB. The long-term effects of chlorpropamide on insulin, C-peptide, and proinsulin secretion. Diabetes Care 1982; 5: 427-429.
25. Duckworth WC, Solomon S, Kitabchi AE. Effect of chronic sulphonylurea therapy on plasma insulin and proinsulin levels. J Clin Endocrinol Metab 1974; 35: 585-591.
26. Davies MJ, Metcalf J, Day JL, Grenfell A, Gray IP, Hales CN. Effect of sulphonylurea therapy on plasma insulin, intact proinsulin, and 32,33 split proinsulin in subjects with Type 2 diabetes mellitus. Diabetic Med 1994; 11: 293-298.
27. Phillips DIW, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: Comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabetic Med 1994; 11: 286-292.
28. Panahloo A, Mohamed-Ali V, Denver E, Andres C, Yudkin JS. Proinsulin-like molecules relate to insulin resistance in non-insulin-dependent diabetes. Diabetic Med 1994; 11 (suppl 2): A24.
29. Hutton JC, Rhodes CJ. The enzymology of proinsulin conversion. Cell Biophysics 1991; 19: 57-62.
30. Janka HU, Ziegler AG, Standl E, Mehnert H. Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diabete & Metabolisme 1987; 13: 359-364.
31. Standl E, Janka HU. High serum insulin concentrations in relation to other cardiovascular risk factors in macrovas-cular disease of Type 2 diabetes. Horm Metab Res 1985; 15: 46-51.